^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

    Excerpt:
    ...Quantitative Change in the Sum of Response Evaluation Criteria in Solid Tumors (RECIST) -`Percent Change in Tumor Size (Change in T) in Patients With Genomic PIK3CA Pathway Alteration (PIK3CA Mutation, Amplification, and Fluorescence in Situ Hybridization [FISH] for PTEN Loss)...
    Trial ID:
    NCT03601507
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Anticancer Res
    Title:

    In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer

    Excerpt:
    The PIK3CA-mutant cell lines were more sensitive to BYL719 than the PIK3CA wild-type cell lines.